Vice President and General Manager
D. Scott Edwards, Ph.D. brings to SciFluor an extensive background in pharmaceutical research and development with a record of major accomplishments in the areas of small molecule therapeutics and medical imaging contrast agents. He held a basic research position at Dow Chemical Company from 1983 through 1987 and then began his career in drug discovery and development on joining the medical imaging division of DuPont Pharmaceutical Co. in 1988. At DuPont and Bristol-Myers Squibb, he held positions of increasing responsibility spanning discovery, pre-clinical development, clinical development and regulatory affairs resulting in multiple new drug approvals and the first pediatric extension for an imaging drug. Scott joined SciFluor in 2012 where he leads the drug development efforts including the clinical, regulatory, and quality functions and manages the company's expansive patent estate. Working with specialty contract research organization, Scott has overseen the clinical advancement on SF0166 through two Phase I/II trials.
He holds a bachelor's degree in chemistry from the Georgia Institute of Technology and a Ph.D. in organometallic chemistry from the Massachusetts Institute of Technology.
Board of Directors
William H. Koster is the President and CEO of Northern Pilot Co., LLC, a firm providing guidance to the pharmaceutical industry in the areas of R&D analysis, design and implementation, portfolio management and strategic business development. He began his career at The Squibb Institute for Medical Research in antibiotic research. His work contributed to the discovery of the antibiotic, Azactam, for which he received the Thomas Alva Edison Award from the R&D Council of New Jersey in 1992. Dr. Koster’s career at Bristol-Myers Squibb (BMS) spanned chemistry, biology, and technology operations ultimately leading to his position as senior vice-president overseeing worldwide drug discovery and early clinical development through Phase 2a. He also led the R&D acquisition and integration effort for the purchase of the DuPont Pharmaceutical Company by BMS in 2001. After 30 years with the BMS organization, in 2001 he accepted the position of President and CEO of Neurogen Corporation, a public biotech company (NASDAQ: NRGN) engaged in neuroscience R&D, a position he held until his retirement in 2008. Dr. Koster holds 30 U.S. Patents and is the author of numerous scientific publications and presentations. He was elected to the Connecticut Academy of Sciences and Engineering (now emeritus) and has served on various scientific advisory forums including the Keystone Symposia Scientific Advisory Board and The National Council for Harvard Medicine. In addition, he has served on the board of directors for Neurogen Corporation and Cadus Pharmaceutical Corporation and continues to serve on the boards of eXIthera Pharmaceuticals, Mnemosyne Pharmaceuticals, and Vedantra Pharmaceuticals (Chairman).
Dr. Koster majored in chemistry at Colby College (1966) and then completed his Ph.D. in organic chemistry at Tufts University in 1972.
CEO, Allied Minds
Jill is the President and CEO of Allied Minds and an Executive Director of the Board. Jill brings more than 25 years of experience as an international business leader, including 16 years as CEO of private and public companies in the technology and information services markets.
Most recently, Smith served as Chairman, CEO and President of DigitalGlobe Inc. (NYSE: DGI), a global provider of satellite imagery products and services. Smith started her career as a consultant at Bain & Company, where she rose to become Partner. She subsequently joined Sara Lee as Vice President, and went on to serve as President and CEO of eDial, a VoIP collaboration company, and of SRDS, a business-to-business publishing firm. She also served as Chief Operating Officer of Micron Electronics, and co-founded Treacy & Company, a consulting and boutique investment business.
She currently serves as an independent director on the boards of Endo International plc (NASDAQ: ENDP) and Hexagon (Nasdaq Stockholm: HEXA B).
EVP and General Councel, Allied Minds
Michael serves as Executive Vice President and General Counsel, advising the Board of Directors and senior management on strategic and investment activities, corporate governance and compliance.
Before joining Allied Minds, Michael was a Partner at DLA Piper and Goodwin Procter. At these firms, Michael acted as outside general counsel to public and private companies, investment banks, and private equity and venture capital firms, with an emphasis on serving the needs of growth companies in the technology and life science sectors, and providing counsel on company formation, equity and debt financings, public offerings, mergers and acquisitions, strategic partnerships, intellectual-property transactions, executive compensation, employment law, and other operational and transactional matters. Michael is admitted to the bar in Massachusetts and New York.
Robert brings his extensive knowledge of the Pharmaceutical Industry along with 25 years focused in Ophthalmology to the Board of SciFluor. Robert has been instrumental in building and launching franchises and has extensive leadership experience in sales, marketing, medical affairs and business development at major Eye Care organizations including Shire where he is currently leading the Global Ophthalmology Franchise. He has held numerous leadership positions at Bausch + Lomb, Inspire and Allergan and is recognized for his knowledge and experience in Ophthalmology, his strategic relationships with industry leaders and professionals in Eye Care. He holds a Masters in Business Administration and a Bachelor of Science from Northeastern University in Boston, Massachusetts.
Dr. Ritter is the Founder of SciFluor. He is Director at a Max Planck Institute, and has faculty appointments in the Department of Chemistry and Chemical Biology at Harvard University and in the Radiology Department at Massachusetts General Hospital. His research focuses on late-stage fluorination chemistry, including applications in positron emission tomography (PET) imaging, and more broadly to develop practical access to molecules of interest in catalysis, medicine, and materials. Prior to joining Harvard, he completed his post-doctoral fellowship at the California Institute of Technology in 2006. Dr. Ritter has won numerous prestigious awards, is a frequently invited lecturer and has authored more than 60 publications.
Dr. Ritter received his undergraduate education in Braunschweig, Germany, Bordeaux, France, Lausanne, Switzerland, and Stanford, U.S. He holds a master's of science degree from Braunschweig University, Germany, and a master's degree in business administration from Hagen University, Germany. Dr. Ritter received his Ph.D. in organic chemistry from ETH Zurich.
Dr. Furuya is the Founder of SciFluor and a graduate of the Department of Chemistry and Chemical Biology at Harvard University. His work is focused on the late-stage fluorination of complex small molecules and their application in 18F PET. He is a co-inventor on several patents, has authored nearly a dozen scientific publications and has received numerous teaching and graduate fellowship awards.
Dr. Furuya holds a bachelor's degree in pharmaceutical science from Tokyo University and a Ph.D. from Harvard University.
SciFluor Announces Appointment of Robert Dempsey to Board of Directors
read more >
SciFluor Announces Positive Top-Line Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration
read more >
SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
read more >
SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
read more >